Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 171

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease

Open access
Walker, Gareth J., Harrison, James W., Heap, Graham A., Voskuil, Michiel D., Andersen, Vibeke, Anderson, Carl A., Ananthakrishnan, Ashwin N., Barrett, Jeffrey C., Beaugerie, Laurent, Bewshea, Claire M., Cole, Andy T., Cummings, Fraser R., Daly, Mark J., Ellul, Pierre, Fedorak, Richard N., Festen, Eleonora A. M., Florin, Timothy H., Gaya, Daniel R., Halfvarson, Jonas, Hart, Ailsa L., Heerasing, Neel M., Hendy, Peter, Irving, Peter M., Jones, Samuel E., Koskela, Jukka, Lindsay, James O., Mansfield, John C., McGovern, Dermot, Parkes, Miles, Pollok, Richard C. G., Ramakrishnan, Subramaniam, Rampton, David S., Rivas, Manuel A., Russell, Richard K., Schultz, Michael, Sebastian, Shaji, Seksik, Philippe, Singh, Abhey, So, Kenji, Sokol, Harry, Subramaniam, Kavitha, Todd, Anthony, Annese, Vito, Weersma, Rinse K., Xavier, Ramnik, Ward, Rebecca, Weedon, Michael N., Goodhand, James R., Kennedy, Nicholas A., Ahmad, Tariq, for the IBD Pharmacogenetics Study Group · 2019 · JAMA

Abstract

Importance: Use of thiopurines may be limited by myelosuppression. TPMT pharmacogenetic testing identifies only 25% of at-risk patients of European ancestry. Among patients of East Asian ancestry, NUDT15 variants are associated with thiopurine-induced myelosuppression (TIM). Objective: To identify genetic variants associated with TIM among patients of European ancestry with inflammatory bowel disease (IBD). Design, Setting, and Participants: Case-control study of 491 patients affected by TIM and 679 thiopurine-tolerant unaffected patients who were recruited from 89 international sites between March 2012 and November 2015. Genome-wide association studies (GWAS) and exome-wide association studies (EWAS) were conducted in patients of European ancestry. The replication cohort comprised 73 patients affected by TIM and 840 thiopurine-tolerant unaffected patients. Exposures: Genetic variants associated with TIM. Main Outcomes and Measures: Thiopurine-induced myelosuppression, defined as a decline in absolute white blood cell count to 2.5 × 109/L or less or a decline in absolute neutrophil cell count to 1.0 × 109/L or less leading to a dose reduction or drug withdrawal. Results: Among 1077 patients (398 affected and 679 unaffected; median age at IBD diagnosis, 31.0 years [interquartile range, 21.2 to 44.1 years]; 540 [50%] women; 602 [56%] diagnosed as having Crohn disease), 919 (311 affected and 608 unaffected) were included in the GWAS analysis and 961 (328 affected and 633 unaffected) in the EWAS analysis. The GWAS analysis confirmed association of TPMT (chromosome 6, rs11969064) with TIM (30.5% [95/311] affected vs 16.4% [100/608] unaffected patients; odds ratio [OR], 2.3 [95% CI, 1.7 to 3.1], P = 5.2 × 10-9). The EWAS analysis demonstrated an association with an in-frame deletion in NUDT15 (chromosome 13, rs746071566) and TIM (5.8% [19/328] affected vs 0.2% [1/633] unaffected patients; OR, 38.2 [95% CI, 5.1 to 286.1], P = 1.3 × 10-8), which was replicated in a different cohort (2.7% [2/73] affected vs 0.2% [2/840] unaffected patients; OR, 11.8 [95% CI, 1.6 to 85.0], P = .03). Carriage of any of 3 coding NUDT15 variants was associated with an increased risk (OR, 27.3 [95% CI, 9.3 to 116.7], P = 1.1 × 10-7) of TIM, independent of TPMT genotype and thiopurine dose. Conclusions and Relevance: Among patients of European ancestry with IBD, variants in NUDT15 were associated with increased risk of TIM. These findings suggest that NUDT15 genotyping may be considered prior to initiation of thiopurine therapy; however, further study including additional validation in independent cohorts is required.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2019.0709

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 171

Metadata

Authors
Walker, G. J., Harrison, J. W., Heap, G. A., Voskuil, M. D., Andersen, V., Anderson, C. A., Ananthakrishnan, A. N., Barrett, J. C., Beaugerie, L., Bewshea, C. M., Cole, A. T., Cummings, F. R., Daly, M. J., Ellul, P., Fedorak, R. N., Festen, E. A. M., Florin, T. H., Gaya, D. R., Halfvarson, J., Hart, A. L., Heerasing, N. M., Hendy, P., Irving, P. M., Jones, S. E., Koskela, J., Lindsay, J. O., Mansfield, J. C., McGovern, D., Parkes, M., Pollok, R. C. G., Ramakrishnan, S., Rampton, D. S., Rivas, M. A., Russell, R. K., Schultz, M., Sebastian, S., Seksik, P., Singh, A., So, K., Sokol, H., Subramaniam, K., Todd, A., Annese, V., Weersma, R. K., Xavier, R., Ward, R., Weedon, M. N., Goodhand, J. R., Kennedy, N. A., Ahmad, T., & for the IBD Pharmacogenetics Study Group
Venue
JAMA
Published
2019-02-26
Volume
321
Issue
8
Pages
773
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2917253389
Cited by
171
References
2
FWCI
22.83
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.